Pharmacy News
Published July 15, 2019
A new drug, Zolgensma, was recently approved by the FDA to treat spinal muscular atrophy (SMA) in young children.
What is Zolgensma?
Zolgensma is a gene therapy used to treat children under the age of two with SMA. It is a one-time infusion treatment and the first drug on the market aimed to replace the dysfunctional gene that causes SMA.
How does Premera cover Zolgensma?
Starting July 1, Premera Blue Cross covers Zolgensma based on FDA guidelines for the individual’s age and specific medical condition. Prior authorization is required.
Zolgensma combined with another SMA therapy called Spinraza is considered investigational and is not covered.
If your clients have questions about how their plan covers Zolgensma, have them call the number on the back of their ID card.